Lucid Diagnostics (LUCD)

• Market cap: $105M
• 1 day: -3.74%
• 5 days: -24.82%
• 1 month: 3.26%
• 3 months: -21.37%
• 6 months: -21.97%
• Year to date: 29.72%
• 1 year: 23.26%
• 5 years: -91.24%
• 10 years: -91.24%
• Sector: Healthcare
• Industry: Medical Devices

About: Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

Employees: 70

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

256% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 9

200% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 6

55% more capital invested

Capital invested by funds: $14.1M [Q1] → $21.9M (+$7.77M) [Q2]

49% more funds holding

Funds holding: 47 [Q1] → 70 (+23) [Q2]

6.71% more ownership

Funds ownership: 10.79% [Q1] → 17.5% (+6.71%) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $2.5
• Avg. target: $2.75
• High target: $3

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

BTIG Mark Massaro	$2.5	Buy Reiterated	10 Sep 2025
Needham Mike Matson	$3	Buy Reiterated	13 Aug 2025